MeiraGTx Holdings PLC
MGTX6.590USD
+0.100+1.54%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
516.64MCap. mercado
PérdidaP/E TTM
Información de MeiraGTx Holdings PLC Compañía
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
Información de la empresa
Código de la empresaMGTX
Nombre de la empresaMeiraGTx Holdings PLC
Fecha de salida a bolsaJun 08, 2018
Fundada en2018
Director ejecutivoDr. Alexandria Forbes, Ph.D.
Número de empleados381
Tipo de títulosOrdinary Share
Fin del año fiscalJun 08
Dirección450 East 29Th Street
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10016
Teléfono16468607985
Sitio Webhttps://meiragtx.com/
Código de la empresaMGTX
Fecha de salida a bolsaJun 08, 2018
Fundada en2018
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.41M
-3.26%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
972.65K
-2.41%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
+4.44%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.00K
+150.00%
Amb. Martin Indyk, Ph.D.
Amb. Martin Indyk, Ph.D.
Independent Director
Independent Director
35.00K
+133.33%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionados
Cambio
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.41M
-3.26%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
972.65K
-2.41%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
+4.44%
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.00K
+150.00%
Desglose de ingresos
No datos encontrados
No datos encontrados
Por negocio
Por región
No datos encontrados
Accionista
Hora de actualización: vie., 11 de abr
Hora de actualización: vie., 11 de abr
Estadísticas de accionistas
Tipo
Estadísticas de accionistas
Accionista
Proporción
Perceptive Advisors LLC
15.95%
Sanofi
15.47%
Johnson & Johnson Innovation-JJDC, Inc.
8.42%
Adage Capital Management, L.P.
6.38%
Prosight Capital
5.57%
Other
48.20%
Estadísticas de accionistas
Accionista
Proporción
Perceptive Advisors LLC
15.95%
Sanofi
15.47%
Johnson & Johnson Innovation-JJDC, Inc.
8.42%
Adage Capital Management, L.P.
6.38%
Prosight Capital
5.57%
Other
48.20%
Tipo
Accionista
Proporción
Hedge Fund
20.60%
Corporation
20.50%
Private Equity
15.95%
Venture Capital
8.42%
Investment Advisor
7.03%
Investment Advisor/Hedge Fund
5.71%
Individual Investor
4.36%
Research Firm
1.07%
Bank and Trust
0.09%
Other
16.28%
Participación institucional
Hora de actualización: mar., 4 de mar
Hora de actualización: mar., 4 de mar
Periodo de informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
230
77.61M
98.43%
+22.67M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
2022Q4
257
33.39M
69.27%
-47.74K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
12.58M
15.95%
--
--
Dec 31, 2024
Sanofi
12.20M
15.47%
+12.20M
--
Dec 31, 2024
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.42%
--
--
Dec 31, 2024
Adage Capital Management, L.P.
5.03M
6.38%
-194.52K
-3.72%
Dec 31, 2024
Prosight Capital
4.39M
5.57%
-509.73K
-10.40%
Dec 31, 2024
Adena Estate Inc.
3.27M
4.14%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.64M
3.35%
+278.31K
+11.79%
Dec 31, 2024
683 Capital Management LLC
2.42M
3.06%
-135.00K
-5.29%
Dec 31, 2024
Woodline Partners LP
1.54M
1.95%
+1.54M
--
Dec 31, 2024
Forbes (Alexandria)
1.46M
1.85%
+58.91K
+4.21%
Feb 21, 2025
Ver más
ETF relacionados
Hora de actualización: dom., 6 de abr
Hora de actualización: dom., 6 de abr
Nombre
Proporción
Invesco NASDAQ Future Gen 200 ETF
0.54%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.03%
SPDR S&P International Small Cap ETF
0.02%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Ver más
Invesco NASDAQ Future Gen 200 ETF
Proporción0.54%
iShares Micro-Cap ETF
Proporción0.07%
ProShares Ultra Nasdaq Biotechnology
Proporción0.05%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.03%
SPDR S&P International Small Cap ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.01%
iShares Russell 2000 Growth ETF
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
No datos encontrados
División de acciones
Fecha
Tipo
Relación
No datos encontrados
Fecha
Tipo
Relación
No datos encontrados